Cirsium Biosciences Scales Custom Equipment for Plant-Based AAV Production

According to a recent LinkedIn post from Cirsium Biosciences, the company has internally developed custom “infiltrator” equipment to support its plant-based adeno-associated virus, or AAV, production workflows. The post describes how an initial small-scale system built in 2022 enabled manual infiltration of five plants at a time and became central to the company’s process.

The LinkedIn post further highlights a new, larger infiltrator designed to handle over 100 plants simultaneously, with automated and highly controlled workflows. This evolution suggests a move toward greater production scalability and process control, which could be important for future cost efficiencies, capacity expansion, and competitive positioning in plant-based biologics and gene therapy manufacturing.

For investors, the emphasis on proprietary process equipment development may indicate a strategy to build internal know-how and potential barriers to entry around Cirsium Biosciences’ platform. While the post does not disclose commercialization timelines, regulatory milestones, or financial figures, the focus on scaling infrastructure points to preparatory steps for eventual larger-scale manufacturing and potential partnerships with biopharmaceutical firms.